(RLYB) Rallybio Corporation Business Model Canvas Research

Clinical research sites are core partners for Rallybio Corporation because Phase I and Phase II studies depend on investigator networks to run dosing, monitor safety, and read early efficacy signals. These sites turn a candidate into decision-grade data, and without them Rallybio cannot move programs from first-in-human testing into proof-of-concept.

• Run early safety and efficacy trials
• Support rapid site activation
• Enable data for go or no-go decisions

Rallybio Corporation relies on manufacturing and development vendors because clinical-stage biotech firms usually outsource about 70%-80% of CMC work, including assay, formulation, and supply-chain services. That cuts fixed plant costs and lets Rallybio keep capital focused on trials and program progress.

• Outsourced CMC lowers fixed infrastructure needs.
• Vendors support assay, formulation, and supply.
• Capital can stay in clinical development.

Rallybio Corporation co-develops with AbCellera, Exscientia, and Johnson & Johnson to widen its technical reach across antibody discovery, AI-led design, and late-stage development. These alliances also spread program risk, which matters for a small biotech managing a lean pipeline and limited capital.

• Shares R and D cost and risk
• Expands discovery and design depth
• Supports faster program advancement

Rallybio Corporation’s regulatory and translational planning turns each asset into a clear IND, trial, and approval path; that matters in rare disease, where small patient pools make biomarker-backed evidence and fast agency alignment decisive. Rare diseases affect about 300 million people worldwide across 7,000+ conditions, so regulatory strategy is a core value driver, not a back-office task.

• Map IND-ready packages early.
• Use translational data to de-risk trials.
• Align with FDA and EMA fast.

Rallybio Corporation's partnership IP is a core asset because its 3 major collaborations with AbCellera, Exscientia, and Johnson & Johnson bring outside know-how plus shared rights that can speed programs and support future commercialization. For a small-cap biotech, that kind of IP can matter more than lab scale, since it can reduce R&D risk and widen partner-led value creation.

• 3 strategic collaborations
• External know-how from top partners
• Shared IP can support commercialization

Rallybio Corporation’s key resources are its New Haven, Connecticut base and its scientific team, which must handle rare-disease biology and clinical execution at the same time. For a clinical-stage company, this internal know-how is the asset that turns a small 2025–2026 organization into a focused drug-development engine.

• New Haven headquarters anchors the team.

• Rare-disease expertise drives program design.

• Clinical execution is the core capability.

RLYB332 targets severe anemia driven by ineffective erythropoiesis and iron overload, a high-burden space that affects millions of patients worldwide and still lacks enough disease-modifying options. It also widens Rallybio Corporation beyond FNAIT and complement, giving the pipeline a second rare-disease growth pillar.

• Severe unmet need
• Broadens pipeline mix
• Targets anemia and iron overload

Rallybio Corporation uses antibodies, affibodies, and small molecules, so it can match the right modality to each rare-disease target instead of forcing one tool across all programs. That flexibility can widen its addressable pipeline and support faster moves from biology to clinic, especially in areas where only a few hundred thousand patients in the U.S. drive the market.

• Multiple modalities fit different targets.
• Broader rare-disease pipeline reach.
• Better odds of program-specific fit.

Scientific communication is core for Rallybio Corporation: the Company must keep sharing 2025 clinical and pipeline data with physicians, researchers, and regulators. Conference talks and journal papers raise credibility, while a 2025 year-end cash position of $64.5 million would signal enough runway to keep that dialogue going.

• Share data to build trust.
• Use conferences to widen reach.
• Use publications to support partners.

If approved, Rallybio Corporation therapies would need specialist prescribing and close HCP-led support, because rare diseases affect about 300 million people worldwide across roughly 7,000 conditions. The model would center on healthcare professionals, with education and monitoring built in for each patient.

• HCPs lead prescribing support.
• Rare-disease care needs monitoring.
• Education drives adherence.

Scientific conferences are a high-visibility channel for Rallybio Corporation because a single poster or oral talk can reach thousands of investors and researchers at one meeting, helping the Company frame pipeline progress and keep rare-disease assets in view. For a clinical-stage biotech, that exposure matters because data readouts, safety updates, and biomarker results often move sentiment before revenue exists.

• Builds investor and researcher awareness
• Positions pipeline assets with data
• Supports clinical-stage credibility

Rallybio Corporation uses public filings and corporate updates as its main information channel, with SEC reports and press releases laying out pipeline status, trial milestones, and collaborations. These disclosures help keep investors and partners aligned on execution risk and program progress.

In 2025 filings, that transparency mattered because biotech value depends on milestone timing, cash use, and clinical readouts, not sales. One line: the market prices the next data point.

• SEC filings show pipeline progress.
• Trial updates mark key value events.
• Collaboration news signals external validation.

Severe anemia patients are a long-term, high-need segment for Rallybio Corporation’s RLYB332, especially those with ineffective erythropoiesis and transfusion-driven iron overload. WHO estimates about 1.9 billion people live with anemia worldwide, and complex hematology cases can need repeated transfusions, raising iron overload risk after roughly 10-20 units.

• Chronic, severe need
• Complex hematology patients
• Iron overload risk rises fast

Biopharma collaborators are Rallybio Corporation’s co-development and business customers, including AbCellera, Exscientia, and Johnson & Johnson. These 3 named partners can bring funding, technical know-how, and a route to market, which helps Rallybio expand its pipeline without carrying all R&D cost alone.

• 3 named biopharma partners

• Can fund and de-risk programs

• Support pipeline expansion and commercialization

Rallybio Corporation’s collaboration and licensing costs are a biotech staple: deals can require upfront fees, milestone payments, and shared development spend, plus extra cost for IP access and partner support. In 2025, this model still meant external partners could drive a meaningful share of program cost, especially in rare-disease development.

These payments are often variable, so cash burn can jump when a program advances.

• Upfront fees hit cash first
• Milestones rise with progress
• Shared R&D lowers solo spend
• IP and support add fixed costs

Rallybio Corporation’s general and administrative expense covers public-company overhead: personnel, finance, legal, compliance, and New Haven headquarters costs. This is the fixed base that supports SEC reporting and board governance, even before any product revenue.

• Personnel and compliance drive most G&A.
• New Haven HQ adds office overhead.
• Public-company reporting keeps costs recurring.

Rallybio Corporation has no marketed product today, so future product sales are still pre-revenue. If an FNAIT or rare-disease candidate wins approval, direct sales could become the main stream, and orphan-drug pricing can support premium net prices because patient pools are small and unmet need is high.

• No current product sales
• Approval could unlock direct sales
• FNAIT may support premium pricing
• Rare-disease demand is niche

Royalties are a contingent revenue stream for Rallybio Corporation: if it out-licenses an asset and a partner commercializes it, Rallybio can earn a percentage of net sales. This is standard biotech monetization, but the cash flow depends on the partner’s launch, pricing, and demand, so timing is uncertain.

• Paid only after partner sales start
• Scales with net sales, not headcount
• No partner success, no royalty cash